Rutgers University in New Brunswick, New Jersey, recently announced the establishment of the Omar Boraie Chair in Genomic Science at the Rutgers Cancer Institute of New Jersey, according to NewsWise. Named after a New Brunswick developer, Omar Boraie, the newly announced chairship was created to generate new research in precision medicine. Boraie pledged $1.5 million to establish this endowed chair position because of his interest in cancer research and a desire to inspire others to give to the cause of cancer research.
Precision medicine is a newer field in the field of genomic sciences that analyzes cancer tumors on their genetic levels. This is groundbreaking because it helps oncologists to individualize treatments and therapies for cancer patients which can improve their prognosis. The field has shown such promise that President Obama recently unveiled a Precision Medicine Initiative that will focus on finding a cure for cancer as well as other diseases.
Rutgers has been a trailblazer in the field through its use of genomic sequencing as a medical approach to cancer patients’ treatment. This method has been particularly successful in discovering treatments for those patients who have rare forms of cancer or poor prognoses, or those who have had unsuccessful treatment therapies in the past.
The creation of this chair position was part of Rutgers’ “18 Chair Challenge” campaign. In the campaign, an anonymous donor is donating a $1.5 million match for 18 new chair positions, which will create an endowment of $3 million for each new chair. The endowment in the field of genomic science reveals Rutgers’ commitment to supporting this newer field in cancer research.
The first chairperson named to the Omar Boraie Chair in Genomic Science is Shridar Ganesan, who is recognized as one of the world’s leading researchers in medical oncology. Ganesan is the Associate Director for Translational Science at the Rutgers Cancer Institute and an associate professor at the Rutgers Robert Wood Johnson Medical School. Ganesan came to Rutgers in 2005 from the renowned Dana-Farber Cancer Institute at Harvard Medical School. Ganesan is confident that the new endowment will lead to new findings in cancer biology that will benefit cancer patients and provide hope for those patients with even the most difficult forms of the disease.

Leave a Reply

Your email address will not be published. Required fields are marked *